AR104979A2 - Derivados de quinazolina y formas cristalinas del mismo como inhibidores de vegfr - Google Patents

Derivados de quinazolina y formas cristalinas del mismo como inhibidores de vegfr

Info

Publication number
AR104979A2
AR104979A2 ARP160101750A ARP160101750A AR104979A2 AR 104979 A2 AR104979 A2 AR 104979A2 AR P160101750 A ARP160101750 A AR P160101750A AR P160101750 A ARP160101750 A AR P160101750A AR 104979 A2 AR104979 A2 AR 104979A2
Authority
AR
Argentina
Prior art keywords
azd2171
quinazoline
maleate salt
salt
derivatives
Prior art date
Application number
ARP160101750A
Other languages
English (en)
Inventor
Mcabe James
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30776508&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR104979(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR104979A2 publication Critical patent/AR104979A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Una sal maleato de 4-((4-fluoro-2-metil-1H-indol-5-il)oxi)-6-metoxi-7-(3-(pirrolidin-1-il]propoxi)quinazolina, (AZD2171), formas cristalinas., procesos de preparación, composiciones farmacéuticas que las contienen, y usos en la fabricación de medicamentos para el tratamiento de enfermedades asociadas ala angiogénesis y/o mayor permeabilidad vascular. Reivindicación 2: Una sal maleato de AZD2171, de acuerdo con la reivindicación 1, caracterizada porque está en la forma cristalina, Forma A. Reivindicación 3: Una sal maleato de AZD2171, de acuerdo con la reivindicación 1, caracterizada porque está en la forma cristalina, Forma B. Reivindicación 7: Una sal maleato de AZD2171, de acuerdo con la reivindicación 2, en la forma cristalina, Forma A, caracterizada porque dicha sal tiene un patrón de difracción de rayos X sobre polvo con picos específicos en aproximadamente 2-q = 21,5, 16,4, 24,4, 20,7, 25,0, 16,9, 12,1, 22,2, 17,4 y 17,6º. Reivindicación 12: Una sal maleato de AZD2171, de acuerdo con la reivindicación 3, en la forma cristalina, Forma B, caracterizada porque dicha sal tiene un patrón de difracción de rayos X sobre polvo con picos específicos en aproximadamente 2-q = 24,2, 22,7, 15,7, 12,0, 27,1, 25,0, 17,7, 15,0, 23,1 y 12,6º.
ARP160101750A 2003-12-24 2016-06-10 Derivados de quinazolina y formas cristalinas del mismo como inhibidores de vegfr AR104979A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0330002.7A GB0330002D0 (en) 2003-12-24 2003-12-24 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
AR104979A2 true AR104979A2 (es) 2017-08-30

Family

ID=30776508

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP040104882A AR046993A1 (es) 2003-12-24 2004-12-22 Derivados de quinazolina
ARP160101750A AR104979A2 (es) 2003-12-24 2016-06-10 Derivados de quinazolina y formas cristalinas del mismo como inhibidores de vegfr

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP040104882A AR046993A1 (es) 2003-12-24 2004-12-22 Derivados de quinazolina

Country Status (33)

Country Link
US (6) US20070129387A1 (es)
EP (1) EP1699782B1 (es)
JP (2) JP5009628B2 (es)
KR (1) KR101240872B1 (es)
CN (2) CN102153543B (es)
AR (2) AR046993A1 (es)
AT (1) ATE471936T1 (es)
AU (1) AU2004303590B2 (es)
BR (1) BRPI0417958B8 (es)
CA (1) CA2548662C (es)
CY (1) CY1110730T1 (es)
DE (1) DE602004027833D1 (es)
DK (1) DK1699782T3 (es)
ES (1) ES2345776T3 (es)
GB (1) GB0330002D0 (es)
HK (1) HK1095325A1 (es)
HR (1) HRP20100455T1 (es)
IL (1) IL176308A (es)
MX (1) MXPA06007191A (es)
MY (1) MY145143A (es)
NO (1) NO336613B1 (es)
NZ (1) NZ547547A (es)
PL (1) PL1699782T3 (es)
PT (1) PT1699782E (es)
RS (1) RS51387B (es)
RU (1) RU2425043C2 (es)
SA (1) SA05250464B1 (es)
SI (1) SI1699782T1 (es)
TW (1) TWI339119B (es)
UA (1) UA91332C2 (es)
UY (1) UY28702A1 (es)
WO (1) WO2005061488A1 (es)
ZA (1) ZA200605225B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482946T1 (de) 1999-02-10 2010-10-15 Astrazeneca Ab Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
PL371486A1 (en) * 2002-02-01 2005-06-13 Astrazeneca Ab Quinazoline compounds
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
BRPI0508959A (pt) * 2004-03-23 2007-08-14 Astrazeneca Ab uso de azd2171 ou de um sal do mesmo farmaceuticamente aceitável, uso de sal maleato de azd2171 e oxaliplatina, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
EP1965801B1 (en) * 2005-12-22 2011-03-23 AstraZeneca AB Combination of azd2171 and pemetrexed
US7851623B2 (en) 2006-11-02 2010-12-14 Astrazeneca Ab Chemical process
CL2008000070A1 (es) * 2007-01-17 2008-07-25 Lg Life Sciences Ltd Monosal del acido maleico (3-[({1-[(2-amino-9h-purin-9-il)metil]ciclopropil}oxi)metil]-8,8-dimetil-3,7-dioxo-2,4,6-trioxa-3 lambda 5-fosfanon-1-il-pivalato; composicion farmaceutica que comprende a dicha monosal; y uso para el tratamiento del virus h
WO2010072348A1 (en) * 2008-12-23 2010-07-01 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
CA2775027A1 (en) * 2009-09-25 2011-03-31 Kyorin Pharmaceutical Co., Ltd. Maleic acid salt and crystal thereof
WO2013188279A1 (en) * 2012-06-12 2013-12-19 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing cediranib
US9007866B2 (en) 2013-04-23 2015-04-14 Tessera Inc. Retention optimized memory device using predictive data inversion
JP6426194B2 (ja) 2013-11-01 2018-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態及びその使用
JP6426195B2 (ja) * 2013-11-01 2018-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態及びその使用
CN105461698A (zh) * 2014-09-12 2016-04-06 杭州普晒医药科技有限公司 西地尼布盐及其晶型、以及其制备方法和药物组合物
WO2017035170A1 (en) * 2015-08-24 2017-03-02 Pliva Hrvatska D.O.O Solid state forms of cediranib maleate
AU2017221268B2 (en) 2016-02-15 2024-02-15 Astrazeneca Ab Methods comprising fixed intermittent dosing of cediranib
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP2019533641A (ja) 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10255725B2 (en) * 2016-11-16 2019-04-09 Disney Enterprises, Inc. Augmented reality interactive experience
CN110817898B (zh) * 2018-08-13 2021-09-03 中国科学院大连化学物理研究所 一种具有ats骨架结构的磷酸硅铝分子筛及其制备方法和应用
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81307A0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5411963A (en) * 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
CA2091204C (en) 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
AU686843B2 (en) * 1994-02-23 1998-02-12 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
DE4436509A1 (de) * 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9505651D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd AgrEvo UK Limited
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EP0860433B1 (en) 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19614718A1 (de) 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
DK0912559T3 (da) 1996-07-13 2003-03-10 Glaxo Group Ltd Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
EP0984692A4 (en) 1997-05-30 2001-02-21 Merck & Co Inc ANGIOGENESIS INHIBITORS
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
WO1999010349A1 (en) 1997-08-22 1999-03-04 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
ATE482946T1 (de) * 1999-02-10 2010-10-15 Astrazeneca Ab Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
CZ20021390A3 (cs) 1999-10-19 2002-09-11 Merck & Co., Inc. Inhibitory tyrosinkinázy
AU769222B2 (en) * 1999-11-05 2004-01-22 Genzyme Corporation Quinazoline derivatives as VEGF inhibitors
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US20030118078A1 (en) * 2001-08-10 2003-06-26 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
PL371486A1 (en) 2002-02-01 2005-06-13 Astrazeneca Ab Quinazoline compounds
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
UA91332C2 (uk) 2010-07-26
CN1898232A (zh) 2007-01-17
HRP20100455T1 (hr) 2010-09-30
US9890140B2 (en) 2018-02-13
PL1699782T3 (pl) 2010-10-29
US9556151B2 (en) 2017-01-31
KR101240872B1 (ko) 2013-03-07
US20070129387A1 (en) 2007-06-07
BRPI0417958A (pt) 2007-03-27
NO336613B1 (no) 2015-10-12
US20150025091A1 (en) 2015-01-22
CA2548662C (en) 2013-09-03
DE602004027833D1 (de) 2010-08-05
DK1699782T3 (da) 2010-08-30
JP2007517008A (ja) 2007-06-28
AR046993A1 (es) 2006-01-04
RU2425043C2 (ru) 2011-07-27
SA05250464B1 (ar) 2008-08-27
TWI339119B (en) 2011-03-21
ZA200605225B (en) 2007-05-30
CN102153543A (zh) 2011-08-17
US20170000791A1 (en) 2017-01-05
PT1699782E (pt) 2010-08-04
IL176308A (en) 2013-03-24
NZ547547A (en) 2009-08-28
ES2345776T3 (es) 2010-10-01
AU2004303590A1 (en) 2005-07-07
JP5009628B2 (ja) 2012-08-22
SI1699782T1 (sl) 2010-09-30
US20180170913A1 (en) 2018-06-21
UY28702A1 (es) 2005-07-29
MXPA06007191A (es) 2006-08-23
US20100298357A1 (en) 2010-11-25
AU2004303590B2 (en) 2009-07-30
CN1898232B (zh) 2011-08-17
NO20062703L (no) 2006-07-20
US8859570B2 (en) 2014-10-14
IL176308A0 (en) 2006-10-05
JP2011088936A (ja) 2011-05-06
EP1699782B1 (en) 2010-06-23
EP1699782A1 (en) 2006-09-13
TW200524593A (en) 2005-08-01
RU2006126782A (ru) 2008-01-27
BRPI0417958B8 (pt) 2021-05-25
BRPI0417958B1 (pt) 2019-02-05
GB0330002D0 (en) 2004-01-28
RS51387B (en) 2011-02-28
MY145143A (en) 2011-12-30
US20190375730A1 (en) 2019-12-12
HK1095325A1 (en) 2007-05-04
CA2548662A1 (en) 2005-07-07
KR20060127899A (ko) 2006-12-13
ATE471936T1 (de) 2010-07-15
CN102153543B (zh) 2013-01-02
CY1110730T1 (el) 2015-06-10
WO2005061488A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
AR104979A2 (es) Derivados de quinazolina y formas cristalinas del mismo como inhibidores de vegfr
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
IS6647A (is) Kínasólínafleiður til að meðhöndla æxli
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
UY27592A1 (es) Nuevo uso
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
ES2250416T3 (es) Estimulante de secreciohn de hormona de crecimiento.
ATE299022T1 (de) Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis
CR10056A (es) [(1h-indol-5-il)-heteroariloxi]-(1-aza-biciclo[3.3.1]nonanos como ligandos colinérgicos del n-achr para el tratamiento de trastornos piscóticos y neurodegenerativos
CY1104977T1 (el) Χρηση r-αρυλοπροπιονικων οξεων για την παραγωγη φαρμακων πα την αντιμετωπιση παθησεων ρευματικης φυσεως
RU2008127882A (ru) Лечение пищевода барретта
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
UY26992A1 (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y corticoesteroides
TW200505452A (en) Chemical compounds
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
ATE502641T1 (de) Kombination aus azd2171 und pemetrexed
UY29134A1 (es) Sulfonamidas sustituidas por derivados de bencimidazol, composiciones que la contienen, procedimiento de preparacion y aplicaciones
ATE364586T1 (de) Steigerung der wirksamkeit von wirkstoffen durch micellare zubereitung mit retinolderivaten
UY28357A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
ATE309817T1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs

Legal Events

Date Code Title Description
FC Refusal